Dihydroergotamine mesylate is a Small Molecule owned by Satsuma Pharmaceuticals, and is involved in 5 clinical trials, of which 4 were completed, and 1 is ongoing.

Dihydroergotamine mesylate activates 5-HT1D receptors located on intracranial blood vessels which leads to vasoconstriction, that correlates with the relief of migraine headache and activation of 5-HT1D receptors on sensory nerve endings of the trigeminal system results in the inhibition of pro-inflammatory neuropeptide release.

The revenue for Dihydroergotamine mesylate is expected to reach a total of $580m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Dihydroergotamine mesylate NPV Report.

Dihydroergotamine mesylate is currently owned by Satsuma Pharmaceuticals.

Dihydroergotamine mesylate Overview

Dihydroergotamine mesylate (STS-101, TO-2070) is under development for the treatment of acute migraine. The drug candidate is an ergot alkaloid that acts on 5-HT1D antimigraine receptors. It is administered through nasal dry powder drug delivery system. TO-2070 is based on a nasal powder drug delivery technology that combines a muco-adhesive drug carrier with a proprietary nasal powder drug delivery device.

Satsuma Pharmaceuticals Overview

Satsuma Pharmaceuticals (Satsuma) is biopharmaceutical company. It develops novel therapies for neurological diseases. It is investigating its lead pipeline candidate STS101 is a proprietary investigational drug-device combination product which enables intranasal administration of the anti-migraine drug, dihydroergotamine mesylate (DHE). The company is funded by RA Capital Management, TPG Biotech, Shin Nippon Biomedical Laboratories, Osage University Partners, CAM Capital, and Eventide Asset Management LLC. Satsuma is headquartered in South San Francisco, California, the US.

The operating loss of the company was US$51.2 million in FY2021, compared to an operating loss of US$48.3 million in FY2020. The net loss of the company was US$51.2 million in FY2021, compared to a net loss of US$47.6 million in FY2020.

Quick View – Dihydroergotamine mesylate

Report Segments
  • Innovator
Drug Name
  • Dihydroergotamine mesylate
Administration Pathway
  • Nasal
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Phase III

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.